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Abstract: The homeodomain protein PDX-1 is a critical regulator of pancreatic development and
insulin production in pancreatic β-cells. We have recently shown that PDX-1 is a substrate of
protein kinase CK2; a multifunctional protein kinase which is implicated in the regulation of various
cellular aspects, such as differentiation, proliferation, and survival. The CK2 phosphorylation
site of PDX-1 is located within the binding region of the E3 ubiquitin ligase adaptor protein
PCIF1. To study the interaction between PDX-1 and PCIF1 we used immunofluorescence analysis,
co-immunoprecipitation, GST-pull-down studies, and proximity ligation assay (PLA). For the analysis
of the stability of PDX-1 we performed a cycloheximide chase. We used PDX-1 in its wild-type form
as well as phosphomutants of the CK2 phosphorylation site. In pancreatic β-cells PDX-1 binds to
PCIF1. The phosphorylation of PDX-1 by CK2 increases the ratio of PCIF1 bound to PDX-1. The
stability of PDX-1 is extended in the absence of CK2 phosphorylation. Our results identified protein
kinase CK2 as new important modulator of the stability of PDX-1.
Keywords: pancreatic and duodenal homeobox protein PDX-1; PDX-1 C-terminus interacting factor
PCIF1; protein kinase CK2; protein stability
1. Introduction
Protein kinase CK2 is a multifunctional and pleiotropic protein kinase that plays critical roles in
cell differentiation, proliferation, and survival [1–3]. CK2 is a multi-subunit protein kinase which is
generated by the association of two catalytic α- and/or α’- subunits (38–42 kDa) with a dimer of the
27 kDa non-catalytic β-subunit. Up to now CK2 is known to phosphorylate more than 400 different
proteins and the number is rapidly increasing [4]. CK2 phosphorylation of proteins can modulate
the subcellular localization, change DNA binding and transcription factor activities, to mention but a
few [4]. There are several reports that CK2 also affects the stability or break-down of proteins [5–10].
Recently, we identified the transcription factor PDX-1 as a new substrate for protein kinase
CK2 [11]. The pancreatic duodenal homeobox 1 protein (PDX-1), also known as IPF-1, IDX-1, STF-1,
GSF, and IUF-1, is expressed in the region of the developing foregut that later becomes the duodenum,
distal stomach, and pancreas [12,13]. As development proceeds, PDX-1 expression gets restricted to
mostly the hormone-producing β and δ cells of the endocrine pancreas. Murine PDX-1 is a 284 amino
acid-long protein with a central homeodomain flanked by proline-rich N- and C-terminal domains.
A transactivation domain maps to the N-terminus. The homeodomain contains the DNA binding
domain as well as a nuclear localization signal [14,15]. Although the function of the C-terminus is
poorly understood, there is some indication that the C-terminus has an inhibitory function whereas
other data showed, that the C-terminus is required for full transactivation function [16–18]. PDX-1 is
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a phosphoprotein and a number of different kinases is known to phosphorylate PDX-1 (for review
see [19]). Recently, we identified two phosphorylation sites for protein kinase CK2 in the C-terminus
of PDX-1, namely threonine 231 and serine 232 [11] and found that the transcription factor activity of
PDX-1 is modulated by the CK2 phosphorylation. Moreover, both phosphorylation sites are in the
center of the binding domain for PCIF1 (PDX-1 C terminus interacting factor 1) [20], a protein which
targets PDX-1 for ubiquitination and proteasomal degradation [21]. PCIF1, or the human homologue
SPOP (Speckle type POZ (pox virus and zinc finger protein)), acts as E3 ubiquitin ligase adaptor which
binds the Cullin moiety of the E3 ubiquitin ligase complex to their unique substrate binding adaptor
proteins [22]. In the present study, we have analyzed whether the stability of PDX-1 and its interaction
with PCIF1 might be affected by the phosphorylation of CK2 within the PCIF1 binding region.
2. Results
We have previously shown that PDX-1 is a substrate for protein kinase CK2 [11]. Phosphorylation
sites were identified as threonine 231 and serine 232 of mouse PDX-1. We further showed that
the transcription factor activity of PDX-1 is modulated by CK2 phosphorylation. Since the CK2
phosphorylation site of PDX-1 lies in the middle of the interaction domain with the E3 ubiquitin ligase
adaptor protein PCIF1 we wanted to know whether the interaction with and the stability of PDX-1
might be affected by CK2 phosphorylation.
A prerequisite for a physical interaction is the co-localization of two proteins. In a first experiment
we performed an in situ immunofluorescence analysis with PDX-1 and PCIF1 specific antibodies in
mouse pancreatic MIN6 β-cells. Figure 1a shows the localization of PDX-1 (red) and the localization of
PCIF1 (green). Merging both images (yellow color) revealed that PDX-1 and PCIF1 colocalize mostly
in the nucleus. The fact that both proteins are present in the same place does not necessarily mean
that they interact. In a further experiment we, therefore, performed a co-immunoprecipitation with
a PDX-1 specific antibody. As there is a lower abundance of PCIF1 in β insulinoma cells ([20], and
our observation), we transfected MIN6 cells with eukaryotic expression constructs for PDX-1 and
PCIF1. After transfection, cell extracts were incubated with a PDX-1 specific antibody. Proteins of
the immunocomplex were separated by SDS polyacrylamide gel electrophoresis and analyzed by
immunoblot analysis with a PDX-1 specific and a FLAG-tag antibody against PCIF1. The result
shown in Figure 1b demonstrates that both proteins were immunoprecipitated with the PDX-1 specific
antibody (lane IP).
A more refined type of analysis to study the interaction of proteins in situ, is the proximity
ligation assay PLA [23]. To analyze the role of a CK2 phosphorylation of PDX-1 we inhibited the
CK2 activity with the at present most specific CK2 inhibitor CX-4945 [24]. By incubating MIN6 cells
for four hours in the presence of 10 µM CX-4945, CK2 activity was reduced to 20% of the activity of
untreated cells (−) (Figure 2b). As the transcription factor activity of PDX-1 is glucose responsive [25]
and as the interaction with PCIF1 might also be affected by glucose we used glucose concentration
of 5 and 25 mM. MIN6 cells were seeded on coverslips, glucose was withdrawn from the medium
for 5 h and then added again in a concentration of 5 mM (normoglucose) or 25 mM (high glucose) to
stimulate glucose-dependent processes. MIN6 cells were subjected to a PLA analysis with a PDX-1
and a PCIF1 specific antibody. A positive interaction was visualized by red fluorescent dots (Figure 2c).
Counting the dots in three different independent areas demonstrated that glucose had no influence
on the interaction (average 177 vs. 173 dots/50 cells). However, when cells were treated with the
CK2 inhibitor, the mean value decreased to 150 dots/50 cells (85%) under normoglucose and even
to 79 dots/50 cells (45%) under high glucose (Figure 2d). Thus, the interaction of both proteins is
significantly reduced in the presence of the CK2 inhibitor; the reduction is most obvious under high
glucose conditions.
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Figure 1. PDX-1 and PCIF1 interaction in MIN6 cells. (a) Immunofluorescence analysis of endogenous 
PDX-1 and PCIF1. MIN6 cells were cultured on coverslips and stained with a polyclonal rabbit 
antiserum against PDX-1, a goat polyclonal antiserum against PCIF1 (SPOP K-13) and DAPI for nuclei 
staining. As secondary antibodies, ALEXA-FluorTM488 or ALEXA-FluorTM594 were used. 
Immunofluorescence was analyzed using a Zeiss Axioskop fluorescence microscope (Zeiss, Jena, 
Germany). Magnification: 400×; and (b) co-immunoprecipitation of PDX-1 and PCIF1 from 
transfected MIN6 cell extracts. MIN6 cells were transfected with PDX-1 and FLAG-tagged PCIF1 for 
24 h. Two mg of cell extract were precleared twice with a mixture of protein A sepharose beads and 
CL 4-B agarose beads over a period of 1 h. The supernatants were incubated with a rabbit PDX-1 
antibody for 2 h. The immunoprecipitated proteins were separated by 12.5% SDS polyacrylamide gel 
electrophoresis, transferred to a polyvinylidenfluoride (PVDF) membrane and analyzed by Western 
blot with the mouse monoclonal M2 antibody against the FLAG-tag of PCIF1 and the polyclonal 
rabbit antiserum against PDX-1. WE: whole cell extract (20 µg), input: 10% of cell extracts used for 
immunoprecipitation, C: control without antibody, IP: immunoprecipitate, two independent 
precipitations. 
To prove that the interaction of both proteins is phosphorylation-sensitive we performed a GST-
pull-down assay with wild-type and phosphomutant proteins [26]. PCIF1 is not a known CK2 
substrate; by in silico scanning of the polypeptide chain no sequence with the known consensus motif 
for CK2 (S/TxxD/E [27]) was found. Thus, we used in vitro translated [35S]-methionine labeled PCIF1 
in its wild-type form and incubated it with GST-tagged PDX-1 wild-type and the CK2-
phosphodeficient (PDX-1T231A/S232A) or the CK2-phosphomimicking (PDX-1T231D/S232E) mutant. GST-
tagged PDX-1 and bound PCIF1 were pulled-down with GSH sepharose, complexes were eluted and 
separated on an SDS polyacrylamide gel. Proteins were stained with Coomassie blue and subjected 
to autoradiography. The result is shown in Figure 3a. The Coomassie blue staining demonstrated that 
we used equal amounts of GST-PDX-1 forms. All PDX-1 variants bound to PCIF1, however, the 
phospho-mimicking mutant PDX-1T231D/S232E bound considerably more PCIF1. After evaluation of four 
independent experiments the binding capacity of the D/E mutant was calculated to be 1.5 fold better 
than for wild-type or the AA mutant (Figure 3b). Thus, we conclude that the CK2 phosphorylated 
form of PDX-1 binds better to the E3 ubiquitin ligase adaptor protein PCIF1. 
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Figure 2. Influence of glucose and CK2 inhibitor CX-4945 on the interaction of PDX-1 and PCIF1. (a) 
Chemical structure of CX-4945 (Silmitasertib); (b) in vitro phosphorylation assay in the absence and 
presence of CX-4945. MIN6 were treated with DMSO as control (0 µM) or with 10 µM CX-4945 for 24 
hours. Kinase activity of CK2 in the cell extracts was measured with the synthetic CK2 specific peptide 
substrate, RRRDDDSDDD, in the presence of [32P]ATP. Results from three individual experiments 
are shown; the activity in the control cells was set to 100%; (c) Duolink® in situ proximity ligation 
assay (PLA) of PDX-1 and PCIF1 in MIN6 cells. MIN6 cells were incubated with 5 mM or 25 mM 
glucose for 4 h after 5 h starvation and simultaneously with 10 µM CX-4945 (+) or an equal volume 
DMSO for control (-). Cells were subjected to Duolink® in situ proximity ligation assay using 
antibodies against PDX-1 (polyclonal rabbit antiserum) and PCIF1 (mouse monoclonal antibody 
Figure 2. Influence of glucose and CK2 inhibitor CX-4945 on the interaction of PDX-1 and PCIF1.
(a) Chemical structure of CX-4945 (Silmitasertib); (b) in vitro phosphorylation assay in the absence and
presence of CX-4945. MIN6 were treat d with DMSO as control (0 µM) or with 10 µM CX-4945 for
24 h. Kina e activity of CK2 in the cell extracts was measured with t e synthetic CK2 sp cific peptide
substrate, RRRDDDSDDD, in the presence of [32P]γATP. Results from three individual experiments are
shown; the activity in the control cells was set to 100%; (c) Duolink® in situ proximity ligation assay
(PLA) of PDX-1 and PCIF1 in MIN6 cells. MIN6 cells were incubated with 5 mM or 25 mM glucose
for 4 h after 5 h starv tion and simu taneously w th 10 µM CX-4945 (+) or an equal volume DMSO
for control (−). Cells were subjected to Duolink® in situ proximity ligation assay using antibodies
against PDX-1 (polyclonal rabbit antiserum) and PCIF1 (mouse monoclonal antibody SPOP B-8).
Immunofluorescence was analyzed using a Zeiss Axioskop fluorescence microscope (Zeiss, Jena,
Germany); and (d) quantification of the interaction. Single dots were counted in 50 cells of three
different areas. Experiments in the absence of CX-4945 were used as reference (100%). The bar graph
shows the median results of three independent counts.
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Figure 3. Interaction of PDX-1 and PCIF1 as a function of CK2 phosphorylation. (a) GST pull-down 
analysis of the PCIF1/PDX-1 interaction. About 10 µg GST-PDX-1WT, GST-PDX-1T231A/S232A, or GST-
PDX-1T231D/S232E were incubated with 7.5 µL of in vitro translated and [35S]-methionine labeled PCIF1 
protein. The formed complex was coupled to GSH sepharose. Proteins eluted from the affinity resins 
were analyzed on a 12.5% SDS polyacrylamide gel, stained with Coomassie blue and afterwards 
subjected to autoradiography; and (b) after densitometric analysis of the PDX-1 and PCIF1 signals the 
PCIF1/PDX-1 ratio was calculated and the relative values were presented as bar graphs referred to 
the interaction of wild-type PDX-1 and PCIF1. 
In the next step we asked whether binding of PDX-1 to PCIF1 might have an influence on the 
stability of PDX-1. To determine the stability of PDX-1 wild-type, as well as of the CK2 
phosphorylation mutant PDX-1T231A/S232A, MIN6 cells were transfected with PDX-1 constructs and 30 
h after transfection cells were treated with cycloheximide for an inhibition of protein synthesis. Cells 
were either extracted immediately (0 h) or after 3, 6, 12, or 24 h of treatment. The cell extracts were 
analyzed on an SDS polyacrylamide gel followed by Western blot with an anti-FLAG-tag-antibody. 
As shown in Figure 4a, over a time course of 24 h, wild-type PDX-1 degraded more rapidly than the 
mutant PDX-1T231A/S232A. The experiment was done in triplicate, the resulting bands for PDX-1 were 
Figure 3. Interaction of PDX-1 and PCIF1 as a function of CK2 phosphorylation. (a) GST pull-down
analysis of the PCIF1/PDX-1 interaction. About 10 µg GST-PDX-1WT, GST-PDX-1T231A/S232A,
or GST-PDX-1T231D/S232E were incubated with 7.5 µL of in vitro translated and [35S]-methionine labeled
PCIF1 protein. The formed complex was coupled to GSH sepharose. Proteins eluted from the affinity
resins were analyzed on a 12.5% SDS polyacrylamide gel, stained with Coomassie blue and afterwards
subjected to autoradiography; and (b) after densitometric analysis of the PDX-1 and PCIF1 signals the
PCIF1/PDX-1 ratio was calculated and the relative values were presented as bar graphs referred to the
interaction of wild-type PDX-1 and PCIF1.
In the next step we asked whether binding of PDX-1 to PCIF1 might have an influence on
the stability of PDX-1. To determine the stability of PDX-1 wild-type, as well as of the CK2
phosphorylation mutant PDX-1T231A/S232A, MIN6 cells were transfected with PDX-1 constructs and
30 h after transfection cells were treated with cycloheximide for an inhibition of protein synthesis. Cells
were either extracted immediately (0 h) or after 3, 6, 12, or 24 h of treatment. The cell extracts were
analyzed on an SDS polyacrylamide gel followed by Western blot with an anti-FLAG-tag-antibody.
As shown in Figure 4a, over a time course of 24 h, wild-type PDX-1 degraded more rapidly than the
mutant PDX-1T231A/S232A. The experiment was done in triplicate, the resulting bands for PDX-1 were
scanned, quantified and normalized to the corresponding α-tubulin loading control. The mean ratios
(PDX-1/ α-tubulin) +/- standard deviation of the densitometric quantification are shown in Figure 4b.
The calculated half-life of wil -typ PDX-1 was 12 h, which is in the range of published data [28,29]
whereas, the half-life of mutant PDX-1T231A/S232A was about 24 h. Thus, PDX-1, which can no longer
be phosphorylated by CK2, is much more stable than the corresponding wild-type f rm.
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It was shown that PCIF1 and Cullin 3 target PDX-1 for ubiquitination [21]. Therefore, we next 
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transferred to a PVDF membrane followed by Western blotting using anti-FLAG tag and anti--
tubulin antibodies. 
As shown in Figure 4c, treatment with MG132 led to a distinct accumulation of wild-type PDX-
1 protein, whereas no significant change was observed in the PDX-1 double alanine mutant protein 
level. After quantification of the expression of both forms from three independent experiments the 
increase for the wild-type protein turned out to be more than 50% (Figure 4d). This observation meant 
that the phosphorylation mutant was less sensitive than wild-type PDX-1 to MG132 treatment, which 
Figure 4. Stability of P X-1WT and PDX-1T231A/S232A in MIN6 cells. (a) MIN6 cells were transfected
with FLAG-PDX-1WT or the double mutant FLAG-PDX-1T231A/S232A. Thirty hours post transfection,
cells were treated with 100 µg/ml cycloheximide (CHX) to inhibit the protein synthesis. Cells were
either extracted immediately (0 h) or after 3, 6, 12, and 24 h of treatment. The cell extract was
analyzed on a 12.5% SDS poly crylamid gel and transferr d to a PVDF membrane followed by
Wester blotting with anti-FLAG tag- and anti-α-tubulin- antibodies. α-tubulin was used as a
loading control. One representative blot out of three is shown; (b) densitometric quantification of
the PDX-1 protein after normalization o the loading control t each time point. Mean ± S.D. stands
for three independent experiments; (c) MIN6 cells transiently tra sfected with plasmids encoding
FLAG-PDX-1WT o FLAG-PDX-1S232A/T231A were treated 48 h post transfection with (+) or without
(−) 5 µM MG132 for 11 h. Cel s wer then lysed and the whole cell extracts were analyzed by Western
blotti g using anti FLAG-tag and ant -α-tubulin antibodies. α-tubuli was analyzed as a loading
con rol. A quantification f the relative FLAG-PDX-1 protein level (FLAG-PDX-1/α-tubulin) is shown
in (d). The results were the mea ± S.D. of three independent experiments.
It was shown that PCIF1 and Cullin 3 target PDX-1 for ubiquitination [21]. Therefore, we
next tested whether the CK2 phosphorylation of PDX-1 might have an influence on its proteasomal
degradation. MIN6 cells were transfected with FLAG-tagged wild-type PDX-1 or with mutant
PDX-1S232A/T231A for 48 h. Cells were treated with or without 5 µM MG132, a proteasome inhibitor,
for another 11 h and lysed. PDX-1 protein levels were analyzed on a 12.5% SDS polyacrylamide
gel and transferred to a PVDF membrane followed by Western blotting using anti-FLAG tag and
anti-α-tubulin antibodies.
As shown in Figure 4c, treatment with MG132 led to a distinct accumulation of wild-type PDX-1
protein, whereas no significant change was observed in the PDX-1 double alanine mutant protein level.
After quantification of the expression of both forms from three independent experiments the increase
for the wild-type protein turned out to be more than 50% (Figure 4d). This observation meant that the
phosphorylation mutant was less sensitive than wild-type PDX-1 to MG132 treatment, which indicated
that the non-phosphorylated form was more resistant to proteasomal degradation whereas wild-type
PDX-1 was targeted for degradation by the proteasome machinery.
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From these various results we conclude that CK2 phosphorylation of PDX-1 has a massive
influence on the stability of PDX-1 and this phosphorylation confers susceptibility of PDX-1 protein to
proteasomal degradation.
3. Discussion
Protein kinase CK2 is classified as a serine/threonine kinase with more than 400 different
substrates, which indicates the pleiotropic functions of CK2 [4]. We have recently identified PDX-1
as a substrate of CK2. PDX-1 is phosphorylated by CK2 at threonine 231 and serine 232 in the
C-terminus [11]. By using CK2 inhibitors as well as by using PDX-1 where the threonine and the serine
residues were mutated to alanine, it was shown that the CK2 phosphorylation of PDX-1 regulates its
transcription factor activity. Here, we show that CK2 phosphorylation of PDX-1 regulates its stability.
Furthermore, we demonstrated that CK2 phosphorylation influences the binding of PDX-1 and PCIF1,
a factor which targets PDX-1 for proteasomal degradation. Our observations are summarized in
Figure 5.
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ligase protein PCIF1 in a phosphorylated form. PCIF1 targets PDX-1 to the proteasome where it is
ubiquitinated and subsequently degraded; and (b) upon CK2 inhibition, T231 and S232 of PDX-1 are
not phosphorylated. As these important residues of the phosphodegron are not phosphorylated, the
interaction with PCIF1 is reduced and PDX-1 is more stable.
The stability of some proteins, such as myc [7], ataxin-3 [30], SAG-SCFE3 ubiquitin ligase [31],
PML [8], PTEN [9], VHL [10], and NKX3.1 [32], is regulated by CK2 phosphorylation. Here, we
show that the use of PDX-1, which could no more be phosphorylated by CK2 resulted in an elevated
stability of PDX-1. There are some other reports showing that the stability of PDX-1 is regulated by
phosphorylation. PDX-1 is phosphorylated in vivo on serine 61 and/or serine 66 by glycogen synthase
kinase 3 (GSK3) in pancreatic β-cells [29]. This phosphorylation targets the protein for degradation by
the proteasome, which results in a decreased half-life for the PDX-1 protein. In contrast, treatment of
cells with a proteasome inhibitor led to distinct accumulation of GSK3 phosphorylated PDX-1 protein
at serine 61/serine 66, whereas no significant change was observed for total PDX-1 protein. PDX-1 is
also phosphorylated by the DNA-dependent protein kinase (DNA PK) and by the mammalian sterile
20-like kinase-1 (MST1) in the N-terminus at threonine 11 [33,34]. This phosphorylation resulted in the
ubiquitination and degradation of PDX-1. It is of interest that under diabetic conditions, MST1 was
strongly activated in β-cells of human and mouse islets. An et al. [35] recently reported that murine
PDX-1 is phosphorylated at serine 269 by the homeodomain interacting protein kinase 2 (HIPK2).
Treatment of β-cells with high glucose concentrations resulted in an enhanced phosphorylation at
serine 269. It was further shown that HIPK2 phosphorylation at this site affected neither the stability
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of PDX-1 nor its transactivation potential. However, this phosphorylation affected the subcellular
distribution of PDX-1 in MIN6 cells. The same site is also target of p38 MAPK phosphorylation [36].
p38 interacted with PDX-1 and phosphorylated the human protein at serine 268, which resulted
in an increased expression and decreased ubiquitination of PDX-1. In βTC3 insulinoma cells this
phosphorylation is induced upon a stimulus with glucagon like peptide GLP1 and acts as a positive
regulator of PDX-1. In line with these observations we found that the PDX-1 stability was also affected
by the CK2 phosphorylation of PDX-1 at threonine 231 and serine 232.
For the ubiquitination and subsequent proteasomal degradation of proteins a highly controlled
orchestra of activating E1 enzymes, E2 conjugating enzymes and E3 ubiquitin ligase enzymes is
necessary [36]. Targeting the substrates for ubiquitin-mediated degradation is the responsibility
of adaptor proteins. Murine PCIF1, or its 100% human homologue SPOP, was identified as such
an adaptor protein, which bridges the Cullin 3 moiety of an E3 ligase and its substrate [22];
PDX-1 was identified as one of these PCIF1-binding substrates [20]. Zhuang et al. [37] published
a characteristic PCIF1 binding consensus motif which consists of Π-π-S-S/T-S/T (Π = nonpolar,
π = polar). In SRC-3, another PCIF1-binding substrate, the binding region was defined as DVSST,
where the polar and nonpolar residues occur in a reversed order [38]. For the interaction of PDX-1
and PCIF1, amino acids 210–238 of mouse PDX-1 are essential amino acids [20]. When checking
this region (RSSGTPSGGGGGEEPEQDCAVTSGEELLA), we noticed the sequence 229AVTS232 which
is quite similar to the SRC-3 binding motif of PCIF1. The threonine and serine residue within this
consensus motif are the phosphorylation sites for protein kinase CK2. We found that the binding of
PDX-1 to PCIF1 was enhanced upon using phospho-mimicking mutants where T231 and S232 were
exchanged by an acid residue; on the other hand, PDX-1 binds weaker to PCIF1 upon inhibition of
CK2. There are several examples that binding of E3 ubiquitin ligases, like β-TRCP or FBW7, to their
substrates is modulated by phosphorylation [39–41]. So-called phosphodegrons were also found for
the PCIF1 substrates SRC-3 [38] and the ERG oncoprotein [42]; in both cases serine residues within the
consensus motif are phosphorylated by CK1. The phosphorylation triggers the interaction between
the E3 ligase adaptor protein PCIF1 and its substrate and thereby activates degradation.
PCIF1 is a nuclear protein with a speckled pattern of nuclear staining [20], PDX-1 and PCIF1
co-localize in the nucleus [20] and our observation). PCIF1 together with Cullin 3 mediates the
ubiquitination of PDX-1 which was shown in ubiquitin overexpression systems [20,43]. Here, we
have shown the influence of CK2 phosphorylation of PDX-1 upon its ubiquitination and proteasomal
degradation by using the proteasome inhibitor MG132 [44]. We observed that the phosphorylation
mutant of PDX-1 had a significant prolonged half-life (24 h) compared with the wild-type PDX-1 (12 h).
Furthermore, the wild-type PDX-1, rather than the mutant form of PDX-1, accumulated in response
to treatment with the proteasome inhibitor MG132 in β-cells. Thus, all these findings let us conclude
that CK2-phosphorylated PDX-1 underwent rapid degradation in β- cells by the proteasomal pathway,
further supporting the idea that modification by CK2 phosphorylation served as an important part to
regulate the stability of the PDX-1 protein.
Some studies suggested a stimulatory effect of glucose on PDX-1 phosphorylation [16,22,32],
whereas others showed that glucose stimulation of β-cells decreases PDX-1 phosphorylation [15].
Moreover, a decrease in C-terminal phosphorylation of PDX-1 was associated with an increase
in protein stability. Here, we demonstrated a decrease in binding of PDX-1 to PCIF1 upon CK2
inhibition, which may be the reason for the enhanced stability of the phospho-deficient alanine mutant.
The significance of phosphorylation of PDX-1 for the interaction is more obvious under high glucose
conditions, a situation where the presence of a fully functional PDX-1 is extremely important for the
regulation of insulin transcription, secretion and regulation of blood glucose homeostasis. Therefore,
inhibition of CK2 seems to be an option to increase the stability of PDX-1 and subsequently, the level
of insulin. A CK2 inhibitor is currently under clinical investigation for the treatment of cancer [24].
It may be an interesting question whether this inhibitor can also be used to treat Diabetes mellitus.
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4. Materials and Methods
4.1. Cell Culture and Treatment
The mouse cell line MIN6 [45] was maintained in Dulbecco’s modified Eagle’s medium
(Sigma-Aldrich, Munich, Germany) containing 5.5 mM D-glucose and 2 mM glutamine supplemented
with 15% (v/i) fetal bovine serum and 100 µM β-mercaptoethanol in humidified 5% CO2/95% air
at 37 ◦C.
The CK2 inhibitor CX-4945 (SelleckChem, Munich, Germany) was dissolved in dimethyl
sulfoxide (DMSO) to a 10 mM stock solution, which was used to treat the cells with the given final
concentration. In control experiments we used the same volume of the solvent DMSO alone. To check
the stability of the PDX-1 protein, MIN6 cells were transfected with FLAG-tagged PDX-1WT or with
mutant PDX-1T231A/S232A and then further incubated for 30 h. The proteasome inhibitor MG132
(Calbiochem, Darmstadt, Germany) was dissolved as 10 mM stock solution in DMSO and applied on
transfected cells 48 h post transfection in a final concentration of 5 µM for 11 h.
4.2. Plasmids
Full-length mouse PDX-1 was subcloned into the mammalian expression vector p3xFLAG/
CMV-7.1 (Sigma-Aldrich, Munich, Germany) using the BamH1 site. PDX-1 phosphorylation
mutants were generated using a QuikChange site-directed mutagenesis kit (Stratagene, La Jolla,
CA, USA) according to the manufacturer’s protocol. As another eukaryotic expression vector we used
pcDNA3.1-PDX-1WT [11]. PDX-1WT and mutants were also ligated with the bacterial expression vector
pGEX-4T-1 (GE Healthcare, Freiburg, Germany) via its BamH1 site [11]. For mammalian expression
of human PCIF1 we used pFLAG-CMV-2-SPOP, a kind gift of C. H. Chung, Seoul, South Korea [46].
The cDNA of human PCIF1 was also cloned into the BamH1/Xho1 sites of pET28a. All constructs
generated by cloning and mutagenesis were verified by DNA sequencing.
4.3. Extraction of Cells and Western Blot Analysis
For harvesting, cells were scraped off the plate and sedimented by centrifugation (7 min, 4 ◦C,
400× g). Cells were washed with cold phosphate-buffered saline (PBS) and lysed with the double
volume of RIPA buffer (50 mM Tris/HCl, pH 8.0, 150 mM NaCl, 0.5% sodium desoxycholate,
1% Triton X-100, 0.1% sodium dodecylsulfate) supplemented with the protease inhibitor cocktail
completeTM (Roche Diagnostics, Mannheim, Germany). After lysis, cell debris was removed by
centrifugation. The protein content was determined according to a modified Bradford method
(BioRad, Munich, Germany). SDS polyacrylamide gel electrophoresis and Western blot analysis
was performed essentially as described [11]. PDX-1 was detected using a polyclonal antiserum from
rabbit. The mouse monoclonal antibody FLAG M2 (F1804) and the mouse monoclonal antibody
β-tubulin (clone DM1A) were from Sigma-Aldrich (Munich, Germany).
4.4. Co-Immunoprecipitation
For co-immunoprecipitation experiments, MIN6 cells were transfected with pcDNA3.1-PDX-1 and
pFLAG-CMV-2-SPOP using Effectene™ according to the provider (Qiagen, Hilden, Germany). 24 h
after transfection, cells were extracted and 4 mg of total protein was subjected to immunoprecipitation.
The cell lysates were pre-cleared twice with a mixture of protein A sepharose beads and CL 4-B
sepharose beads (GE Healthcare, Freiburg, Germany) over a period of 1 h. The supernatant was
incubated with a rabbit anti PDX-1 antibody for 2 h. Beads were washed four times with PBS (137 mM
NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4). Bound proteins were eluted with SDS
sample buffer (130 mM Tris-HCl, pH 6.8, 0.02% bromophenol blue (w/v), 10% β-mercaptoethanol, 20%
glycerol (v/v), and 4% SDS), and analyzed by Western blot with the M2 FLAG-antibody for PCIF1 and
the polyclonal rabbit antiserum against PDX-1. Proteins were visualized by the ECL Lumilight system
of Roche Diagnostics (Mannheim, Germany).
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4.5. Cycloheximide Chase
MIN6 cells were either transfected with FLAG-PDX-1wt or FLAG-PDX-1T231A/S232A mutant using
Effectene™ (Qiagen, Hilden, Germany) as recommended by the manufacturer. Thirty hours after
transfection, MIN6 cells were cultured in growth medium containing 100 µg/mL cycloheximide
(Sigma-Aldrich GmbH, Munich, Germany) for 0, 3, 6, 12, or 24 h. Cells were harvested and lysed with
RIPA buffer as described earlier and extracts were subjected to SDS polyacrylamide gel electrophoresis
and Western blot analysis. The experiment was performed in triplicate. The PDX-1 signals were
scanned and densitometrically quantified using the Quantity One (version 4.6.7.) software from
BioRad (Munich, Germany). The values were normalized to an α-tubulin loading control which was
analyzed on the same gel. The mean values +/- standard deviation of three independent experiments
were represented in the corresponding graphs.
4.6. Immunofluorescence Analysis
MIN6 cells were seeded in a 6 cm plate on coverslips, cultured overnight, and immunofluorescence
analysis was performed as described [47]. For identification of the PDX-1 protein, a rabbit polyclonal
antiserum generated against the C-terminus of PDX-1 was used. PCIF1 was detected with a
goat polyclonal antibody (SPOP K-13 from Santa Cruz Biotechnologies, Heidelberg, Germany).
Secondary antibodies were goat anti rabbit AlexaFluorTM594 and donkey anti goat AlexaFluorTM488
(Invitrogen, Karlsruhe, Germany). Nuclei were visualized by 4,6-diamino-2-phenylindole (DAPI)
staining. Analysis was carried out by fluorescence imaging performed on an Axioskop fluorescence
microscope (Zeiss, Jena, Germany).
4.7. Duolink® in Situ Proximity Ligation Assay
For detection of the interaction between the PDX-1 protein and PCIF1, we used the Duolink®
in situ Proximity Ligation Assay (PLA, Sigma-Aldrich GmbH, Munich, Germany) according to
the manufacturer’s protocol with MIN6 cells. PDX-1 was detected with the polyclonal rabbit
antiserum, PCIF1 with a mouse monoclonal antibody (SPOP B-8, Santa Cruz Biotechnologies,
Heidelberg, Germany). Detection of the interaction signals was carried out by fluorescence imaging
performed on an Axioskop fluorescence microscope (Zeiss, Jena, Germany).
4.8. GST-Pull Down Assay
The pull-down assay was essentially done as described by Sun et al. [48]. Purified GST-tagged
proteins (10 µg) were immobilized on GSH-sepharose and equilibrated with PBS-T binding buffer
(PBS, pH 7.4, 1% Tween 20). Immobilized proteins were incubated for 2 h at 4 ◦C with 7.5 µL of PCIF1
product from an in vitro translation reaction. The translation from a pET28a-PCIF-1 plasmid was done
as recommended by the manufacturer (Promega GmbH, Mannheim, Germany). After washing with
cold PBS-T, bound proteins were eluted with SDS sample buffer (65 mM Tris-HCl, pH 6.8, 2% SDS,
5% β-mercaptoethanol, 10% glycerol, 0.01% bromophenol blue) and analyzed by SDS polyacrylamide
gel electrophoresis, followed by protein staining with Coomassie blue and autoradiography.
4.9. In Vitro Phosphorylation
To determine the activity of CK2 after its inhibition, cells were treated with CX-4945 or left
untreated, lysed, and the extracts were used in a kinase filter assay. In this assay we measured
the incorporation rate of [32P]-phosphate into the synthetic CK2 specific substrate peptide with the
sequence RRRDDDSDDD [14]. Twenty microliter kinase buffer (50 mM Tris/HCl, pH 7.5, 100 mM
NaCl, 10 mM MgCl2, 1 mM dithiotreitol (DTT)) containing 30 µg protein were mixed with 30 µL CK2
mix (25 mM Tris/HCl, pH 8.5, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 50 µM ATP, 0.19 mM substrate
peptide) containing 10 µCi/500 µl [32P]γ ATP. The mixture was spotted onto a P81 ion exchange paper.
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The paper was washed three times with 85 mM H3PO4. After treatment with ethanol, the paper was
dried and the Čerenkov radiation was determined in a scintillation counter.
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